Zydus Secures FDA Priority Review for Saroglitazar NDA in Primary Biliary Cholangitis with November 2026 PDUFA Date

A November 27, 2026 PDUFA date now anchors Zydus's U.S. regulatory calendar for saroglitazar magnesium, after the FDA granted priority review to the company's NDA for primary biliary cholangitis, a designation that compresses the standard review window from twelve months to six and signals the agency's assessment of unmet medical need in this rare hepatic condition.

The NDA submission rests on data from the Phase 3 EPICS-III trial, which demonstrated statistically significant biochemical response alongside a favorable safety profile in PBC patients. For regulatory affairs leads tracking the NDA pathway, the data package will draw scrutiny around the primary endpoint construct, typically alkaline phosphatase reduction and total bilirubin normalization under current PBC guidance, and how Zydus's clinical evidence aligns with FDA's evolving expectations for surrogate endpoints in rare liver disease.

Saroglitazar is a dual PPAR-alpha/gamma agonist already approved in India for diabetic dyslipidemia and non-alcoholic steatohepatitis, giving Zydus an existing GMP manufacturing baseline for the active pharmaceutical ingredient. That history is operationally relevant: a priority review timeline leaves limited runway for any post-submission chemistry, manufacturing, and controls remediation. Plant heads and QA directors supporting the NDA will need pre-approval inspection readiness aligned to 21 CFR Part 211 well ahead of the Q3 2026 inspection window that a late-November action date implies.

The broader strategic read for Indian specialty pharma players is equally direct. Zydus is pursuing a de novo U.S. approval for a novel molecular entity in a rare disease indication, a pathway that carries different regulatory architecture than the ANDA route most domestic manufacturers have historically relied upon. A successful approval would establish a replicable template: Phase 3 data generated outside the U.S., a priority review designation, and a manufacturing network rooted in India navigating FDA pre-approval inspection under rare disease NDA conditions.

If the agency approves saroglitazar by the PDUFA date, Zydus would enter a PBC market currently served by obeticholic acid and, more recently, elafibranor and seladelpar, making commercial manufacturing scale-up and supply-chain continuity planning an immediate post-approval operational priority.

Source: Media4Growth via Indian Pharma Post, May 31, 2026.